Previous close | 200.61 |
Open | 199.28 |
Bid | 0.00 x 1800 |
Ask | 0.00 x 800 |
Day's range | 196.00 - 199.28 |
52-week range | 161.65 - 262.00 |
Volume | |
Avg. volume | 535,958 |
Market cap | 10.291B |
Beta (5Y monthly) | 1.37 |
PE ratio (TTM) | 21.75 |
EPS (TTM) | 9.12 |
Earnings date | 20 Feb 2024 - 26 Feb 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 211.04 |
Charles River's (CRL) share price is likely to grow, backed by the strength of the DSA segment.
Joseph Laplume, the Executive Vice President of Corporate Strategy & Development at Charles River Laboratories International Inc (NYSE:CRL), has recently sold 1,850 shares of the company's stock.
Charles River (CRL) and GC4K announce a gene therapy manufacturing collaboration.